Cytosorbents (CTSO) Cost of Revenue (2011 - 2026)

Cytosorbents' Cost of Revenue history runs 16 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Cost of Revenue rose 959.69% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (up 21.88% YoY) and the FY2025 annual result came in at $10.6 million, down 1.27% from the prior year.
• Cost of Revenue was $2.7 million for Q1 2026 at Cytosorbents, up from $2.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $4.5 million in Q3 2022 and bottomed at -$9.9 million in Q4 2022.
• A 5-year average of $1.8 million and a median of $2.4 million in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 415.68% — and 2026, when it jumped 959.69%.
• Cytosorbents' Cost of Revenue stood at -$9.9 million in 2022, then soared by 123.8% to $2.3 million in 2023, then advanced by 23.42% to $2.9 million in 2024, then slipped by 16.09% to $2.4 million in 2025, then increased by 12.51% to $2.7 million in 2026.
• Business Quant data shows CTSO's Cost of Revenue at $2.7 million in Q1 2026, $2.4 million in Q4 2025, and $2.8 million in Q3 2025.